No connection

Search Results

AMN vs IART

AMN
AMN Healthcare Services, Inc.
BEARISH
Price
$20.49
Market Cap
$787.1M
Sector
Healthcare
AI Confidence
78%
IART
Integra LifeSciences Holdings Corporation
NEUTRAL
Price
$9.90
Market Cap
$771.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AMN
--
IART
--
Forward P/E
AMN
30.31
IART
3.86
P/B Ratio
AMN
1.22
IART
0.74
P/S Ratio
AMN
0.29
IART
0.47
EV/EBITDA
AMN
7.87
IART
8.54

Profitability

Gross Margin
AMN
29.37%
IART
56.23%
Operating Margin
AMN
1.33%
IART
12.44%
Profit Margin
AMN
-10.14%
IART
-31.58%
ROE
AMN
-35.9%
IART
-39.9%
ROA
AMN
1.17%
IART
2.39%

Growth

Revenue Growth
AMN
-7.7%
IART
-1.7%
Earnings Growth
AMN
321.3%
IART
--

Financial Health

Debt/Equity
AMN
1.37
IART
1.95
Current Ratio
AMN
1.05
IART
2.54
Quick Ratio
AMN
0.94
IART
1.19

Dividends

Dividend Yield
AMN
--
IART
--
Payout Ratio
AMN
0.0%
IART
0.0%

AI Verdict

AMN BEARISH

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.

Strengths
Consistently beats earnings estimates with an average surprise of over 90% in the last four quarters
Recent quarterly EPS growth (Q/Q) of +30.0% shows potential operational improvement
Operating margin remains positive at 1.33% despite overall net losses
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and high risk of continued deterioration
Negative profit margin (-10.14%) and ROE (-35.90%) indicate persistent unprofitability and poor capital efficiency
Revenue declining YoY by 7.70%, reflecting shrinking top-line and potential market share loss
IART NEUTRAL

IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.

Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)

Compare Another Pair

AMN vs IART: Head-to-Head Comparison

This page compares AMN Healthcare Services, Inc. (AMN) and Integra LifeSciences Holdings Corporation (IART) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile